SARS-CoV-2 Mpro Inhibitors
1 drugsAbout SARS-CoV-2 Mpro
The SARS-CoV-2 main protease (Mpro or 3CLpro) is essential for viral replication, cleaving polyproteins into functional proteins. Inhibiting Mpro halts viral assembly and maturation, disrupting the virus's life cycle and spread.
Mpro is a key drug target for COVID-19, though no genetic evidence currently links Mpro variations to disease severity. The success of Mpro-targeting antivirals underscores its therapeutic significance.
PAXLOVID (co-packaged) is the only FDA-approved drug targeting Mpro, representing a small molecule approach. Pfizer is the sole company with an approved Mpro-targeting drug for infectious disease.
Top SARS-CoV-2 Mpro Drugs
Pfizer is the only company with an approved drug targeting SARS-CoV-2 Mpro.
High market concentration indicates potential for new entrants with differentiated Mpro inhibitors.
SARS-CoV-2 Mpro Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets SARS-CoV-2 Mpro, using small molecule modality.
Exploring alternative modalities like antibodies or peptides represents a whitespace opportunity.
SARS-CoV-2 Mpro Clinical Trials 32 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on SARS-CoV-2 Mpro. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 9 | 5 | 3 | 1 | 63% |
| Phase 2 | 10 | 7 | 1 | 2 | 88% |
| Phase 3 | 9 | 3 | 0 | 6 | 100% |
| Phase 4 | 4 | 2 | 0 | 2 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
SARS-CoV-2 Mpro Drug Approval Timeline (2023 - 2023)
The first and most recent drug approval for Mpro was PAXLOVID (co-packaged) in 2023.
Recent approval suggests an active area, but saturation may occur quickly without innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 21 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on SARS-CoV-2 Mpro. A trial counts if an approved drug acting on SARS-CoV-2 Mpro is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.